Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
Clinical trial NCT05063136 · RECRUITING
Trial details
- NCT number
- NCT05063136
- Sponsor
- Henan Cancer Hospital
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-28
- Primary completion
- 2025-09-01
- Enrollment
- 1979
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.